Single Time Point Immune Function Assay (ImmuKnow TM ) Testing Does Not Aid in the Prediction of Future Opportunistic Infections or Acute Rejection
|
|
- Eleanore Owens
- 5 years ago
- Views:
Transcription
1 Article Single Time Point Immune Function Assay (ImmuKnow TM ) Testing Does Not Aid in the Prediction of Future Opportunistic Infections or Acute Rejection Janna Huskey,* Jane Gralla, and Alexander C. Wiseman* Summary Background and objectives Current assays and tests that are used to determine the degree of immunosuppression in renal transplant recipients are suboptimal. The ImmuKnow TM assay (Cylex TM ), a measure of intracellular CD4 T cell ATP release proposed as a means to quantify cell-mediated immunity in transplant recipients, could be considered as a potential tool to identify patients at risk for opportunistic infections (OI) or acute rejection (AR). Design, setting, participants, & measurements We retrospectively analyzed 1330 ImmuKnow assay values in 583 renal transplant recipients at a single center from 2004 to 2009 and correlated these values with episodes of OI and AR in the subsequent 90 days. Assay values were compared with a control population matched for age, gender, and time post-transplantation. Results In patients with OI (n 94), there were no differences in prior mean assay values compared with matched controls (386 versus 417 ng/ml, P 0.24). In 47 patients with AR, again no differences were detected in prior assay results (390 versus 432 ng/ml, P 0.25) when compared with controls. Low values ( 225 ng/ml) lacked sensitivity and specificity as a predictive test for subsequent OI, as did strong ( 525 ng/ml) values as a predictive test for subsequent AR. Conclusions Our results fail to show an association between single time point ImmuKnow assay values and the subsequent development of an adverse event in the subsequent 90 days. The optimal use of the Immu- Know assay in kidney transplantation has yet to be determined. Clin J Am Soc Nephrol 6: , doi: /CJN *Division of Renal Diseases and Hypertension, Transplant Center, and Department of Pediatrics, University of Colorado, Denver, Colorado Correspondence: Dr. Alexander C. Wiseman, Transplant Center, University of Colorado Denver, Mail Stop F749, AOP 7089, 1635 North Aurora Court, Aurora, CO Phone: ; Fax: ; Alexander. wiseman@ucdenver.edu Introduction Transplant immunosuppression is a balance between the prevention of immunologic injury such as acute rejection and avoiding adverse events such as opportunistic infections, drug toxicity, and malignancy. Current methods used to determine an individual s immune status after kidney transplant include therapeutic drug monitoring, serologic markers (i.e. absolute leukocyte count, serum creatinine, and anti-hla antibodies), and allograft biopsies. Therapeutic drug monitoring can be effective in preventing toxicity and ensuring patient adherence but does not take into account individual variations in metabolism and may not accurately predict the risk of rejection (1,2). To optimize immunosuppressive regimens and avoid untoward events, additional noninvasive methods to assess an individual s immune responsiveness in the clinical setting are necessary. In 2002, the United States Food and Drug Administration (FDA) approved the ImmuKnow TM assay (Cylex TM ) as an assessment of cell-mediated immunity in immunocompromised individuals (3). The test measures increases in intracellular ATP levels released from activated CD4 cells in response to nonspecific mitogenic stimulus. Because the cellular immune response is known to play a key role in acute rejection and in the prevention of opportunistic infections, the ImmuKnow assay may be a potentially useful predictor for the future development of such adverse events (4 7). Since the FDA review, however, few studies have clarified the value of the ImmuKnow assay in the clinical monitoring of patients after kidney transplant. Additionally, most studies have examined the assay characteristics in the presence of disease, rather than its potential as a predictive assay in patients without predefined disease. Because many of these previous studies had small numbers of patients and events, included nonopportunistic infections, and had varying results, we performed a large retrospective analysis of ImmuKnow results obtained over a 5-year period and correlated these values specifically with subsequent clinical events of acute rejection and opportunistic infection. We hypothesized that measurements of CD4 T cell ATP release via the ImmuKnow assay may demonstrate that individuals with high values are at increased risk for rejec- Vol 6 February, 2011 Copyright 2011 by the American Society of Nephrology 423
2 424 Clinical Journal of the American Society of Nephrology tion, whereas those with low values are at increased risk for opportunistic infections. Materials and Methods We performed a single-center retrospective analysis of ImmuKnow assay (T cell assay [TCA]) results obtained in renal transplant recipients from November 2004 to July Inclusion criteria included recipients of a kidney or simultaneous pancreas-kidney transplant 18 years of age, with at least one TCA drawn during the study period. Initial baseline immunosuppression primarily included three-drug immunosuppression with the majority of regimens consisting of prednisone, a calcineurin inhibitor, and an antiproliferative agent. Rabbit antithymocyte globulin induction therapy was used for repeat transplants, African American recipients, simultaneous pancreaskidney transplants, and patients with panel reactive antibody 20%. All of the patients received Pneumocystis carinii prophylaxis for a total of 6 months posttransplant. In the setting of induction therapy, cytomegalovirus (CMV) IgG recipients received valganciclovir for 3 months, whereas CMV IgG recipients of a kidney from a CMV IgG donor received valganciclovir for 6 months. Patients were screened for BK virus (BKV) via urine and blood PCR at 1, 6, 12, and 24 months post-transplant or in the event of a clinical suspicion such as an acute rise in serum creatinine. Urine PCR levels 100 million copies/ml (high grade viruria) or a positive blood PCR (viremia) resulted in a decrease in immunosuppression with follow-up BKV blood/urine testing until urine PCR decreased to less than 100 million copies/ml, whereas patients with BKV viremia and a rise in serum creatinine underwent biopsy to confirm BKV nephropathy. TCA were drawn in three different clinical scenarios and codified as: (1) protocol-based screening at 0, 1, 6, and 12 months post-transplant; (2) testing in the setting of clinical suspicion such as an acute rise in creatinine and/or potential opportunistic infection; and (3) testing of stable patients in the outpatient setting. The latter group included tests drawn at annual visits 2 or more years post-transplant or at any other routine clinic visit outside of the 1, 6, and 12 months in which organ transplant function was stable. TCA were performed at the University of Colorado HLA Laboratory as described previously (3). Whole blood was incubated overnight with phytohemagglutinin. CD4 cells were selected using paramagnetic particles coated with monoclonal CD4 antibodies, lysed to release ATP, and processed through a luminometer to calculate the numeric result, which was also categorized as low ( 225 ng/ml), moderate (226 to 524 ng/ml), or strong ( 525 ng/ml) per manufacturer recommendations. These values were correlated with subsequent clinical events defined as either opportunistic infections (OI) or acute rejection (AR). TCA values drawn within 90 days before a clinical event were selected for analysis. These values were compared with TCA in patients matched for age, gender, and time of testing post-transplant but without clinical events. Further analysis included study of a subset of patients with more than one TCA value preceding the clinical event, for whom changes in TCA values over time were analyzed for the association of the future development of an adverse clinical event. Acute rejection was defined as an acute rise in creatinine that was biopsy-proven or clinically suspected and improved with empiric intravenous corticosteroid therapy. Retrospective capture of all noninfluenza viral infections and fungal infections diagnosed clinically, serologically, and/or histologically during the study period was performed. Throughout the study period, no clinical intervention protocol was implemented based upon TCA results, and clinicians were discouraged from making interventions in immunosuppression based upon these results. An earlier analysis was performed on data collected from November 2004 to November 2007 (8). Noting no correlation between TCA results and clinical events, further data collection proceeded, again without intervention strategies based upon TCA results. This study was performed with the review and approval of the Colorado Institutional Review Board. Statistical Analyses TCA values were compared at baseline using t tests. Categories of TCA were compared for those with OI (or AR) versus all samples from patients with no infection or rejection events using 2 tests. Patients with OI (or AR) versus control patients matched for age, gender, and time since transplantation were compared using McNemar s test on the matched pairs. Odds ratios were calculated using conditional logistic regression, stratified on age and time of test posttransplant. Changes in TCA over time for those with more than one value before an OI or AR event were compared with paired t tests. OI and AR were compared separately. Group sample sizes of 94 infections and 94 controls achieve 80% power to detect a difference of 74 ng/ml in TCA values, and 47 rejections and 47 controls achieve 80% power to detect a difference of 103 ng/ml, with an estimated group SD of 180 ng/ml and a significance level of 0.05 using a twosided two-sample t test. Results 583 patients had a total of 1330 TCA results available for analysis between November 2004 and July 2009 (Table 1). 897 TCA values (67%) were drawn for protocol screening at 0, 1, 6, or 12 months post-transplant. The remaining tests were drawn for a clinical suspicion or other indication (Table 2). The frequency distribution of these results is presented in Figure 1. Overall, there were a total of 180 opportunistic infections in 151 patients (Table 3). There were 101 TCA values that preceded 101 OI in 91 patients. From these 101 tests, a control group could be identified for 94 TCA tests performed in patients without OI, matched for age, gender, and time post-transplant
3 Clin J Am Soc Nephrol 6: , February, 2011 Predictive Value of CD4 Immune Function Assay, Huskey et al. 425 Table 1. Baseline characteristics of the 583 patients included in the study Variable Age at time of transplant (year; mean SD) Gender male 349 (59.9%) female 234 (40.1%) Race African American 48 (8.2%) Asian 10 (1.7%) Hispanic 85 (14.6%) Caucasian 411 (70.5%) other 19 (3.3%) unknown 10 (1.7%) Type of transplant deceased donor 310 (53.2%) living related 153 (26.2%) living unrelated 103 (17.7%) unknown 17 (2.9%) Induction therapy yes 370 (63.4%) no 184 (31.6%) unknown 29 (5.0%) Type of induction therapy thymoglobulin 294 (79.5%) basiliximab 60 (16.2%) other a 16 (4.3%) Immunosuppression regimen at 1 month b tacrolimus and mycophenolic 315 (54%) acid tacrolimus and sirolimus 144 (24.7%) cyclosporine and 13 (2.2%) mycophenolic acid cyclosporine and sirolimus 5 (0.9%) other c 43 (7.4%) unknown 63 (10.8%) a Other induction therapies included OKT3, alemtuzumab, daclizumab, and alefacept. b All of the patients were on prednisone since transplantation. c Included belatacept or everolimus in addition to calcineurin inhibitor or antiproliferative agent. (controls). The remaining seven TCA associated with a subsequent OI did not have matched controls and were excluded from the analysis (Figure 2). There was no statistically significant difference noted when comparing the mean TCA in those associated with a subsequent OI versus controls (386 versus 417 ng/ml respectively, P 0.24; Figure 2). Similar distributions in TCA values were present in both groups (Table 4). Notably, low values ( 225 ng/ml) were not associated with the future development of OI (P 0.58). Within our overall study sample, 35 Table 2. Conditions under which TCA (ImmuKnow) was performed for 1330 tests Indication for Test Number of Tests (n 1330) Protocol screening at 0, 1, 6, 897 (67%) and 12 months Clinical suspicion a 94 (7%) Other b 339 (26%) a Elevated creatinine, opportunistic infections, nonopportunistic infections, and malignancy. b Routine outpatient measurements outside protocol screening (see text). tests were 100 ng/ml, three of which were associated with a subsequent OI. To determine whether changes in TCA values over time may be more predictive of an OI event, we analyzed 49 of the 91 patients with an OI who had more than one preceding TCA value. In these patients, there was no significant difference between prior and subsequent mean values (395 ng/ml versus 354 ng/ml, P 0.15). Twelve of 49 (25%) of these patients had a TCA decrease of 150 ng/ml, seven of 49 patients (14%) had an increase of 150 ng/ml, whereas the remainder (30 of 49 patients, 61%) had a change in TCA of 150 ng/ml. When compared with controls, the calculated sensitivity and specificity of TCA values 226 ng/ml for OI were 21.3 and 83.0%, respectively. The odds ratio (OR) for a low value, stratifying on age and time post-transplant, was NS at 1.34 (95% confidence interval [CI] 0.64 to 2.82, P 0.43) (Table 5). The results were similar when the relationship between low values and OI were compared with all other samples (OR 1.29, 95% CI 0.79 to 2.09, P 0.31, an uncontrolled comparison). There were a total of 122 episodes of acute rejection in 113 patients overall (Table 6). Of 113 patients with 122 episodes of acute rejection, 52 episodes in 52 patients had a TCA in the prior 90 days available for analysis and were able to be matched with 47 age, gender, and time post-transplant controls. Five patients without controls available were excluded from the analysis. When comparing TCA values in those with subsequent acute rejection versus controls, the mean values between the two groups were not statistically different (390 ng/ml in AR versus 432 ng/ml in controls, P 0.25; Figure 3). In patients with acute rejection, 51% of the preceding TCA values were classified as moderate (226 to 524 ng/ml), 26% as low ( 225 ng/ ml), and 23% as strong ( 525 ng/ml) (Table 7). The proportion of those TCA values classified as strong was not significantly different between patients with AR versus controls (P 0.77). There were significantly more low values in individuals with AR when compared with controls (26% versus 7%, P 0.01; Table 7). Within our overall study sample, of 81 tests 700 ng/ml only two were associated with subsequent AR.
4 426 Clinical Journal of the American Society of Nephrology Figure 1. Distribution of TCA (ImmuKnow) results for 1330 tests performed over a 5-year period (2004 to 2009) in 583 patients. Table 3. Opportunistic Infections 2004 to 2009 with and without preceding TCA (ImmuKnow) Type of Infection TCA in the 90 Days before OI No TCA in the 90 Days before OI Total CMV 18 (17.8%) b 30 (38.0%) 48 (26.4%) BKV 58 (57.4%) c 25 (31.6%) 83 (45.6%) HSV 6 (5.9%) 5 (6.3%) 11 (6.1%) VZV 5 (4.9%) 4 (5.0%) 9 (4.9%) EBV 6 (5.9%) d 7 (8.9%) 13 (7.1%) Candida 3 (3.0%) 7 (8.9%) 12 (6.6%) Other a 5 (4.9%) 1 (1.3%) 6 (3.3%) Total HSV, herpes simplex virus; VZV, varicella-zoster virus. a Rhizopus, nocardia, pneumocystis pneumonia, and cryptococcal infections. b CMV infections were identified in the evaluation of gastrointestinal symptoms (n 9), leukopenia (n 4), or other viral presentations (n 5). c The 58 BKV infections included in the analysis were subclassified as BKV nephropathy (n 7), BKV viremia (n 36), and high-grade BKV viruria (n 15) at the time of diagnosis. d All of the EBV infections were identified in the setting of clinical symptoms, none of which were related to post-transplant lymphoproliferative disorder. Of the 47 patients with AR, 11 had more than one preceding ImmuKnow assay value. In two patients the TCA decreased by 150 ng/ml, eight patients had a change in TCA of 150 ng/ml, and one patient increased by 150 ng/ml before an AR event. High TCA values lacked sensitivity and specificity for predicting the development of acute rejection when compared with controls (23.4 and 80.9%, respectively). Figure 2. TCA (ImmuKnow) results in patients with subsequent OI compared with controls. TCA results with a subsequent OI within 90 days were compared with a control group comprised of patients without OI, matched for age and gender and with similar TCA testing within 90 days from transplant date as patients with OI. The mean TCA values were then compared for each group. The OR was not statistically significant compared with controls (OR 1.87, 95% CI 0.47 to 8.38, P 0.48) or compared with all samples (OR 1.15, 95% CI 0.61 to 2.19, P 0.67) (Table 8). Discussion To our knowledge, this is the most comprehensive study to analyze the utility of a single ImmuKnow assay (Cylex TM ) measure in its predictive value for clinical events such as opportunistic infection and/or acute rejection in renal transplant recipients. We found no association between preceding TCA levels
5 Clin J Am Soc Nephrol 6: , February, 2011 Predictive Value of CD4 Immune Function Assay, Huskey et al. 427 Table 4. Distribution of T cell assay (TCA, ImmuKnow) values in the setting of subsequent opportunistic infection (OI) versus controls without OI TCA Result OI (n 94) No OI (n 94) Low ( 225 ng/ml) 20 (21%) 16 (17%) Moderate (226 to (57%) 52 (55%) ng/ml) Strong ( 525 ng/ml) 21 (22%) 26 (28%) The values are the percentages of tests. Table 5. Sensitivity, specificity of a TCA <225 ng/ml, and opportunistic infection Versus Controls Versus All Samples Sensitivity Specificity Odds ratio % confidence interval 0.64 to to 2.09 and the future development of either an OI or AR in the subsequent 3 months. Within our study population, low TCA values ( 225 ng/ml) lacked both sensitivity and specificity for the prediction of OI, as did high values ( 525 ng/ml) for the prediction of AR. The distribution of test values preceding both clinical outcomes was quite variable between low, moderate, and strong values, rendering the interpretation of a single test result of little clinical value for the purposes of defining patients at risk for OI or AR. Prior reports have suggested that low TCA values are associated with both opportunistic infections and nonopportunistic infections. For example, Batal et al. (9) found significantly lower median TCA values in 25 patients with BK viremia when compared with patients with BK viruria and controls during the first 6 months post-transplant. Another study of 12 renal transplant patients with active viral infections (BKV and Epstein-Barr virus [EBV] most common) noted a mean TCA value of ng/ml at the time of diagnosis, and with a reduction in immunosuppression and treatment of the viral infection, the mean TCA value increased to (10). Importantly, these studies address the TCA at the time of disease rather than before the onset of disease. Other small studies have attempted to assess the Immu- Know assay as a predictive test and have reported that low TCA values are associated with an increased incidence of infections in stable transplant recipients on maintenance immunosuppression (11 14). However, these studies were small with relatively few infection episodes compared with our study and included many nonopportunistic or undefined infections. Unlike these prior studies, we specifically defined and included only opportunistic infections, included tests performed both as screening tests in the asymptomatic patient as well as under conditions of clinical suspicion, and compared these results with a control group matched for age/gender/time of testing post-transplant. There is less evidence in the literature correlating ATP release values and acute rejection. In a study of 509 heart, liver, kidney, and small bowel transplant recipients, patients with TCA values 700 ng/ml were 30 times more likely to develop cellular rejection. However, within the cohort of kidney transplant recipients with AR (n 22), the median TCA value was 462 ng/ml (12). Reinsmoen et al. (15) reported that from a 126-patient cohort, pretransplant TCA levels were higher in 18 patients with subsequent acute rejection (occurring at any time after transplant) compared with 57 patients without subsequent rejection (pretransplant TCA ng/ml versus ng/ ml, P 0.04). Additional smaller studies are contradictory, with some suggesting that TCA may have predictive value for AR (14,16,17), while others have not (9). Unlike these previous studies, our study had 2.5 to 10-fold more AR events (a total of 47 rejection episodes in 47 patients), a defined time of event from TCA (3 months), and a comparison with a gender/ age/time match from the transplant control group. In our study the mean ATP release values for patients with AR was classified as moderate, with significantly more patients with AR and a low TCA when compared with controls. These findings demonstrate that patients with moderate or low ImmuKnow assay values still have a strong intact cellular immune response and can experience acute rejection. A number of limitations in our study must be acknowledged. We included ImmuKnow assay values that were drawn within the preceding 90 days before an event for this analysis. This cutoff was selected as a reasonable time frame (quarterly) that transplant centers and care providers outside of a transplant center may consider utilizing the test, particularly after the first year post-transplant. Tests obtained nearer an event (e.g. 2 weeks or 1 months) may be more representative of an individual patient s risk for future clinical events (9,12) but would require significantly more sampling. Another limitation is that, despite standard immunosuppression and use of depleting antibody induction therapy in nearly half of all patients, TCA values within our population were rarely less than 100 ng/ml. Individuals with TCA values 100 ng/ml may indeed be at higher risk of developing an OI as discussed above (11,12). However, of 35 TCA 100 ng/ml, only three were associated with OI in the subsequent 90 days, indicating that extremely low values are not consistently associated with untoward events. Our lack of data in this regard may be due to differences in immunosuppression regimens compared with other studies (not well defined in other reports). Data regarding changes in immunosuppression after TCA measures, which
6 428 Clinical Journal of the American Society of Nephrology Table 6. Classification of acute rejection 2004 to 2009 with and without preceding TCA (ImmuKnow) Classification of Acute Rejection TCA in the 90 Days before AR No TCA in the 90 Days before AR Total (%) Clinical suspicion (39%) Biopsy proven (61%) cellular humoral cellular and humoral Total Table 8. Sensitivity, specificity of a TCA >525, and acute rejection Versus Controls Versus All Samples Sensitivity Specificity Odds ratio % confidence interval 0.47 to to 2.19 Figure 3. TCA (ImmuKnow) results in patients with subsequent AR compared with controls. TCA results with a subsequent AR within 90 days were compared with a control group comprised of patients without AR, matched for age and gender and with similar TCA testing within 90 days from transplant date as patients with AR. The mean TCA values were then compared for each group. Table 7. Distribution of TCA (Immuknow) values in the setting of subsequent AR versus controls without AR TCA Results AR (n 47) No AR (n 47) Low ( 225) 12 (26%) a 3 (6%) Moderate (226 to 524) 24 (51%) 35 (75%) Strong ( 525) 11 (23%) 9 (19%) The values are the percentages of tests. a P 0.01 versus control. could potentially influence the incidence of end points, were not collected. However, our immunosuppression regimens and protocols are not inconsistent with those commonly implemented for kidney transplantation in the United States and thus represent a reasonable real world experience with TCA interpretation. One cannot entirely exclude the possibility of clinical decision making that may have occurred on the basis of test results. However, this practice was discouraged, and an interim analysis in 2007 that suggested a lack of predictive value reinforced this policy (8). We did not perform serial screening for asymptomatic EBV, CMV, or hepatitis C viremia; thus we cannot comment upon the value of ImmuKnow monitoring for these conditions. Finally, it should be reiterated that the sensitivity and specificity as reported in Tables 5 and 8 are calculated based upon the features of our patient population, immunosuppression protocols, and testing protocol and thus may not be applicable to other transplant populations. Our study was designed to test the hypothesis that the ImmuKnow assay could identify patients at risk for acute rejection or opportunistic infection under routine clinical management of renal transplant recipients. It should be clarified that there is no indication for use of the ImmuKnow assay for this purpose and that its FDA approved indication is for the detection of cell-mediated immunity in an immunosuppressed population. Earlier studies have suggested that this test should be used to determine the strength of a patient s immune system and provide guidance in individualizing and minimizing immunosuppression regimens to avoid adverse events (12). Others have suggested that changes in TCA value over time are more predictive of events, a hypothesis that is supported by uncontrolled studies but could not be tested in our series given relatively small numbers of patients with events who had more than one preceding TCA performed (17,18). On the basis of our data and interpreted within the context of our testing protocol, immunosuppression regimens, and 3-month assessment window described, we suggest that immunosuppressive medications not be adjusted solely on the basis of a single TCA measure.
7 Clin J Am Soc Nephrol 6: , February, 2011 Predictive Value of CD4 Immune Function Assay, Huskey et al. 429 In conclusion, ImmuKnow assay measures at a single time point did not identify individuals at risk for the future development of clinically significant events. Further studies are required, perhaps examining changes in ImmuKnow assay values over time, to clarify the role of this test in immune monitoring of kidney transplant recipients. Disclosures None. References 1. Keown PA, on behalf of the International Neoral Renal Transplantation Study Group: Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant 2: , Mahalati K, Belitsky P, Sketris I, West K, Panek R: Neoral monitoring by simplified sparse sampling area under the concentration-time curve: Its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 68: 55 62, Kowalski R, Post D, Schneider MC, Britz J, Thomas J, Deierhoi M, Lobashevsky A, Redfield R, Schweitzer E, Heredia A, Reardon E, Davis C, Bentlejewski C, Fung J, Shapiro R, Zeevi A: Immune cell function testing: An adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 17: 77 88, Rowshani AT, Bemelman FJ, van Leeuwen EM, van Lier RA, ten Berge IJ: Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients. Transplantation 79: , Joosten SA, Ottenhoff TH: Human CD4 and CD8 regulatory T cells in infectious diseases and vaccination. Hum Immunol 69: , Chen Y, Trofe J, Gordon J, Du Pasquier RA, Roy- Chaudhury P, Kuroda MJ, Woodle, ES, Khalili K, Koralnik IJ: Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy. J Virol 80: , Le Moine A, Goldman M, Abramowicz D: Multiple pathways to allograft rejection. Transplantation 73: , Huskey J, Gralla J, Wiseman AC. Use of the Cylex ImmunoKnow assay in the prediction of acute rejection or opportunistic infection following kidney transplantation. J Am Soc Nephrol 19: 9A, Batal I, Zeevi A, Heider A, Girnita A, Basu A, Tan H, Shapiro R, Randhawa P: Measurements of global cellmediated immunity in renal transplant recipients with BK virus reactivation. Am J Clin Pathol 129: , Gautam A, Fischer SA, Yango AF, Gohh RY, Morrissey PE, Monaco AP: Cell mediated immunity (CMI) and post transplant viral infections: Role of a functional immune assay to titrate immunosuppression. Int Immunopharmacol 6: , Millan O, Sanchez-Fueyo A, Rimola A, Guillen D, Hidalgo S, Benitez C, Campistol JM, Brunet M: Is the intracellular ATP concentration of CD4 T-Cells a predictive biomarker of immune status in stable transplant recipients? Transplantation 88[Suppl 3]: S78 -S84, Kowalski RJ, Post DR, Mannon RB, Sebastian A, Wright HI, Sigle G, Burdick J, Elmagd KA, Zeevi A, Lopez- Cepero M, Daller JA, Gritsch HA, Reed EF, Jonsson J, Hawkins D, Britz JA: Assessing relative risks of infection and rejection: A meta-analysis using an immune function assay. Transplantation 82: , Sanchez-Velasco P, Rodrigo E, Valero R, Ruiz JC, Fernandez-Fresnedo G, Lopez-Hoyos M, Pinera C, Palomar R, Layva-Cobian F, Arias M: Intracellular ATP concentrations of CD4 cells in kidney transplant patients with and without infection. Clin Transplant 22: 55 60, Perez-Flores I, Sanchez-Fructuoso A, Santiago JL, Fernandez-Arquero M, Calvo N, de la Concha EG, Barrientos A: Intracellular ATP levels in CD4 lymphocytes are a risk marker of rejection and infection in renal graft recipients. Transplant Proc 41: , Reinsmoen NL, Cornett KM, Kloehn R, Burnette AD, McHugh L, Flewellen BK, Matas A, Savik K.: Pretransplant donor-specific and non-specific immune parameters associated with early acute rejection. Transplantation 85: , Cadillo-Chavez R, de Echegaray S, Santiago-Delpin EA, Rodriguez-Trinidad AT, Camacho-Carrazo B, Alfaro T, Saavedra-Pozo M, Carrasquillo L, González-Caraballo ZA, Morales-Otero LA: Assessing the risk of infection and rejection in Hispanic renal transplant recipients by means of an adenosine triphosphate release assay. Transplant Proc 38: , Israeli M, Yussim A, Mor E, Sredni B, Klein T: Preceeding the rejection: in search for a comprehensive post-transplant immune monitoring platform. Transpl Immunol 18: 7 12, Israeli M, Ben-Gal T, Yaari V, Valdman A, Matz I, Medalion B, Battler A, Sredni B, Kristt D, Klein T.: Individualized immune monitoring of cardiac transplant recipients by noninvasive longitudinal cellular immunity tests. Transplantation 89: , 2010 Received: May 13, 2010 Accepted: September 23, 2010 Published online ahead of print. Publication date available at J.H. and J.G. contributed equally to this manuscript and should be considered co-first authors.
Trends in immune function assay (ImmuKnow; Cylexä) results in the first year post-transplant and relationship to BK virus infection
2565 Nephrol Dial Transplant (2012) 27: 2565 2570 doi: 10.1093/ndt/gfr675 Advance Access publication 13 December 2011 Trends in immune function assay (ImmuKnow; Cylexä) results in the first year post-transplant
More informationPrior Authorization Review Panel MCO Policy Submission
Prior Authorization Review Panel MCO Policy Submission A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.
More informationPrior Authorization Review Panel MCO Policy Submission
Prior Authorization Review Panel MCO Policy Submission A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.
More informationImmune Cell Function Assay
Immune Cell Function Assay Policy Number: 2.04.56 Last Review: 12/2017 Origination: 12/2015 Next Review: 12/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage for
More informationBK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationUse of immune function test in monitoring immunosuppression in liver transplant recipients
Clin Transplant 2012: 26: 826 832 DOI: 10.1111/j.1399-0012.2012.01632.x 2012 John Wiley & Sons A/S. Use of immune function test in monitoring immunosuppression in liver transplant recipients Te HS, Dasgupta
More informationSolid Organ Transplantation 1. Chapter 55. Solid Organ Transplant, Self-Assessment Questions
Solid Organ Transplantation 1 Chapter 55. Solid Organ Transplant, Self-Assessment Questions Questions 1 to 9 are related to the following case: A 38-year-old white man is scheduled to receive a living-unrelated
More informationImmuKnow: A New Parameter in Immune Monitoring of Pediatric Liver Transplantation Recipients
LIVER TRANSPLANTATION 14:893-898, 2008 ORIGINAL ARTICLE ImmuKnow: A New Parameter in Immune Monitoring of Pediatric Liver Transplantation Recipients Moshe Israeli, 1,3 * Tirza Klein, 1,5 * Benjamin Sredni,
More informationBK Virus (BKV) Management Guideline: July 2017
BK Virus (BKV) Management Guideline: July 2017 BK virus has up to a 60-80% seroprevalence rate in adults due to a primary oral or respiratory exposure in childhood. In the immumocompromised renal transplant
More informationEfficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function
ArtIcle Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function Guodong Chen, 1 Jingli Gu, 2 Jiang Qiu, 1 Changxi
More informationEuropean Risk Management Plan. Measures impairment. Retreatment after Discontinuation
European Risk Management Plan Table 6.1.4-1: Safety Concern 55024.1 Summary of Risk Minimization Measures Routine Risk Minimization Measures Additional Risk Minimization Measures impairment. Retreatment
More informationA comparative study of the ATP concentrations in the peripheral CD4 + lymphocytes of living-donor and cadaveric-donor renal transplant recipients
Current Topics in Pharmacology Vol. 21, 2017 A comparative study of the ATP concentrations in the peripheral CD4 + lymphocytes of living-donor and cadaveric-donor renal transplant recipients Kentaro Sugiyama
More informationLiterature Review Transplantation
Literature Review 2010- Transplantation Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of
More informationPUO in the Immunocompromised Host: CMV and beyond
PUO in the Immunocompromised Host: CMV and beyond PUO in the immunocompromised host: role of viral infections Nature of host defect T cell defects Underlying disease Treatment Nature of clinical presentation
More informationLong-term prognosis of BK virus-associated nephropathy in kidney transplant recipients
Original Article Kidney Res Clin Pract 37:167-173, 2018(2) pissn: 2211-9132 eissn: 2211-9140 https://doi.org/10.23876/j.krcp.2018.37.2.167 KIDNEY RESEARCH AND CLINICAL PRACTICE Long-term prognosis of BK
More informationNephrology Grand Rounds
Nephrology Grand Rounds PTLD in Kidney Transplantation Charles Le University of Colorado 6/15/12 Objectives Background Pathogenesis Epidemiology and Clinical Manifestation Incidence Risk Factors CNS Lymphoma
More informationOverview of New Approaches to Immunosuppression in Renal Transplantation
Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute
More informationTopic BKV Polyoma Virus
Topic 13.1. BKV Polyoma Virus Author: Helen Pilmore and Paul Manley GUIDELINES a. We suggest screening high risk kidney transplant recipients for BK polyoma virus (BKV) with quantitative plasma NAT. The
More informationControversies in Renal Transplantation. The Controversial Questions. Patrick M. Klem, PharmD, BCPS University of Colorado Hospital
Controversies in Renal Transplantation Patrick M. Klem, PharmD, BCPS University of Colorado Hospital The Controversial Questions Are newer immunosuppressants improving patient outcomes? Are corticosteroids
More informationImmune Cell Function Assay
Protocol Immune Cell Function Assay (20456) Medical Benefit Effective Date: 04/01/12 Next Review Date: 01/19 Preauthorization No Review Dates: 09/10, 09/11, 01/12, 01/13, 01/14, 01/15, 01/16, 01/17, 01/18
More informationSerum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant
SDC, Patients and Methods Complement-dependent lymphocytotoxic crossmatch test () Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant donor-specific CXM was
More informationRyszard Grenda: Steroid-Free Pediatric Transplantation. Early Steroid Withdrawal in Pediatric Renal Transplantation
Trends in Transplant. 2011;5:115-20 Ryszard Grenda: Steroid-Free Pediatric Transplantation Early Steroid Withdrawal in Pediatric Renal Transplantation Ryszard Grenda Department of Nephrology, Kidney Transplantation
More informationSELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
More informationClinical Aspect and Application of Laboratory Test in Herpes Virus Infection. Masoud Mardani M.D,FIDSA
Clinical Aspect and Application of Laboratory Test in Herpes Virus Infection Masoud Mardani M.D,FIDSA Shahidhid Bh BeheshtiMdi Medical lui Universityit Cytomegalovirus (CMV), Epstein Barr Virus(EBV), Herpes
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: immune_cell_function_assay 11/2009 3/2017 3/2018 1/2018 Description of Procedure or Service Careful monitoring
More informationIntravenous immunoglobulin in BK virus nephropathy
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2014 Intravenous immunoglobulin in BK virus nephropathy Elizabeth I. Anyaegbu Driscoll Children's Hospital Stanley
More informationBelatacept: An Update of Ongoing Clinical Trials
Belatacept: An Update of Ongoing Clinical Trials Michael D. Rizzari, MD University of Wisconsin Madison School of Medicine and Public Health, Madison, Wisconsin Abstract Belatacept is a fusion protein
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationOBJECTIVES. Phases of Transplantation and Immunosuppression
Transplant and Immunosuppression: Texas Transplant Center April 29, 2017 Regina L. Ramirez, Pharm.D., BCPS PGY1 Pharmacy Residency Program Director Clinical Practice Specialist Solid Organ Transplant and
More informationAmerican Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc.
American Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc. 2009 The Authors Journal compilation 2009 The American Society of Transplantation and the American Society of Transplant
More informationEvaluation of a Weight-based Rabbit Anti-thymocyte Globulin Induction Dosing Regimen for Kidney Transplant Recipients
Evaluation of a Weight-based Rabbit Anti-thymocyte Globulin Induction Dosing Regimen for Kidney Transplant Recipients Catherine A. Pennington, 1 Sarah M. Tischer, 1 Eliza Lee, 2 Sun Lee, 2 James Sindelar,
More informationEmerging Drug List EVEROLIMUS
Generic (Trade Name): Manufacturer: Everolimus (Certican ) Novartis Pharmaceuticals NO. 57 MAY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence: For use with cyclosporine
More informationPlease submit supporting medical documentation, notes and test results.
Pharmacy Prior Authorization AETA BETTER HEALTH FLORIDA Valcyte (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date.
More informationLiterature Review: Transplantation July 2010-June 2011
Literature Review: Transplantation July 2010-June 2011 James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Kidney Transplant Top 10 List: July Kidney
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 30 November 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 30 November 2011 NULOJIX 250 mg, powder for concentrate for solution for infusion B/1 (CIP code: 580 415-7) B/2 (CIP
More informationProgress in Pediatric Kidney Transplantation
Send Orders for Reprints to reprints@benthamscience.net The Open Urology & Nephrology Journal, 214, 7, (Suppl 2: M2) 115-122 115 Progress in Pediatric Kidney Transplantation Jodi M. Smith *,1 and Vikas
More informationThis study is currently recruiting participants.
A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation This study is currently recruiting
More informationFor Immediate Release Contacts: Jenny Keeney Astellas US LLC (847)
For Immediate Release Contacts: Jenny Keeney Astellas US LLC (847) 317-5405 Lauren McDonnell GolinHarris (312) 729-4233 ASTELLAS RECEIVES FDA APPROVAL FOR USE OF PROGRAF (TACROLIMUS) IN CONJUNCTION WITH
More informationGeneral Introduction. 1 general introduction 13
General Introduction In The Netherlands 13,000 patients suffer from end stage renal disease (ESRD), which left untreated inevitably results in death. Every year this number increases with approximately
More informationBy the way, I have a transplant..
By the way, I have a transplant.. Transplant patient for non-transplant surgery David Elliott No relevant disclosures Organ donation in Australia - 2017 Survival rates following organ donation have increased
More informationWhat is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham
What is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham SYMPHONY Study Ekberg et al. NEJM 2008 Excluded: DCD kidneys; CIT>30hours;
More informationInduction Immunosuppression With Rabbit Antithymocyte Globulin in Pediatric Liver Transplantation
LIVER TRANSPLANTATION 12:1210-1214, 2006 ORIGINAL ARTICLE Induction Immunosuppression With Rabbit Antithymocyte Globulin in Pediatric Liver Transplantation Ashesh Shah, 1 Avinash Agarwal, 1 Richard Mangus,
More informationHLA and Non-HLA Antibodies in Transplantation and their Management
HLA and Non-HLA Antibodies in Transplantation and their Management Luca Dello Strologo October 29 th, 2016 Hystory I 1960 donor specific antibodies (DSA): first suggestion for a possible role in deteriorating
More informationAlemtuzumab Induction in Non-Hepatitis C Positive Liver Transplant Recipients
LIVER TRANSPLANTATION 17:32-37, 2011 ORIGINAL ARTICLE Alemtuzumab Induction in Non-Hepatitis C Positive Liver Transplant Recipients Josh Levitsky, 1,2 Kavitha Thudi, 1 Michael G. Ison, 1,3 Edward Wang,
More informationPotential etiologies of infection in these patients are diverse, including common and uncommon opportunistic infections.
In the name of God Principles of post Tx infections 1: Potential etiologies of infection in these patients are diverse, including common and uncommon opportunistic infections. Infection processes can progress
More informationAlemtuzumab Induction in Renal Transplantation
original article Induction in Renal Transplantation Michael J. Hanaway, M.D., E. Steve Woodle, M.D., Shamkant Mulgaonkar, M.D., V. Ram Peddi, M.D., Dixon B. Kaufman, M.D., Ph.D., M. Roy First, M.D., Richard
More informationImmunosuppression: evolution in practice and trends,
American Journal of Transplantation 25; 5 (Part 2): 874 886 Blackwell Munksgaard Blackwell Munksgaard 25 Immunosuppression: evolution in practice and trends, 1993 23 Ron Shapiro a,, James B. Young b, Edgar
More informationArticle. Simultaneous Pancreas Kidney Transplant versus Other Kidney Transplant Options in Patients with Type 2 Diabetes
Article Simultaneous Pancreas Kidney Transplant versus Other Kidney Transplant Options in Patients with Type 2 Diabetes Alexander C. Wiseman* and Jane Gralla Summary Background and objectives Current organ
More informationPrevalence and Risk Factors of Recurrent Cytomegalovirus Infection in Kidney Transplant Recipients
TRANSPLANTATION Prevalence and Risk Factors of Recurrent Cytomegalovirus Infection in Kidney Transplant Recipients Mohsen Nafar, 1 Azamolsadat Roshan, 2 Fatemeh Pour-Reza-Gholi, 1 Fariba Samadian, 1 Pedram
More informationBK virus, kidney transplant, polycystic kidney disease. 1-3 Following mild or asymptomatic primary infection, typically early
Received: 22 June 2018 Revised: 17 July 2018 Accepted: 6 August 2018 DOI: 10.1111/tid.12974 ORIGINAL ARTICLE Kidney transplant recipients with polycystic kidney disease have a lower risk of post- transplant
More informationDonor-derived Cell-free DNA Improves DSA-informed Diagnosis of ABMR in Kidney Transplant Patients
Donor-derived Cell-free DNA Improves DSA-informed Diagnosis of ABMR in Kidney Transplant Patients Stanley C. Jordan, MD Director, Division of Nephrology Medical Director, Kidney Transplant Program Medical
More informationRisk factors in the progression of BK virus-associated nephropathy in renal transplant recipients
ORIGINAL ARTICLE Korean J Intern Med 15;3:865-872 http://dx.doi.org/1.394/kjim.15.3.6.865 Risk factors in the progression of BK virus-associated nephropathy in renal transplant recipients Hae Min Lee 1,*,
More informationOUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes
nep_734.fm Page 88 Friday, January 26, 2007 6:47 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology1320-5358 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 200712S18897MiscellaneousCalcineurin
More informationAcute rejection and late renal transplant failure: Risk factors and prognosis
Nephrol Dial Transplant (2004) 19 [Suppl 3]: iii38 iii42 DOI: 10.1093/ndt/gfh1013 Acute rejection and late renal transplant failure: Risk factors and prognosis Luis M. Pallardo Mateu 1, Asuncio n Sancho
More informationBK Viral Infection and Malignancy in Renal Transplantation ~A Case History~
BK Viral Infection and Malignancy in Renal Transplantation ~A Case History~ Mariko Toyoda, MD Department of Nephrology, Japanese Red Cross Kumamoto Hospital Statement of Disclosure The author does not
More informationIncreased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation
Increased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation Gary W Barone 1, Beverley L Ketel 1, Sameh R Abul-Ezz 2, Meredith L Lightfoot 1 1 Department of Surgery
More informationCMV in kidney Transplant recipient: A diagnostic and therapeutic Dilema
CMV in kidney Transplant recipient: A diagnostic and therapeutic Dilema By Mohamed A. Sobh MD,FACP Professor and head of Nephrology Urology and Nephrology Center Mansoura - Egypt Cytomegalovirus Virology
More informationInnovation In Transplantation:
Innovation In Transplantation: Improving outcomes Thomas C. Pearson Department of Surgery Emory Transplant Center CHOA Symposium October 22, 2016 Disclosures Belatacept preclinical and clinical trial were
More informationRecognition and Treatment of Chronic Allograft Dysfunction
Recognition and Treatment of Chronic Allograft Dysfunction Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs
More informationTest Requested Specimen Ordering Recommendations
Microbiology Essentials Culture and Sensitivity (C&S) Urine C&S Catheter Surgical (excluding kidney aspirates) Voided Requisition requirements o Specific method of collection MUST be indicated o Indicate
More informationIntracellular ATP Production By CD4 T Cells Comparison of Different Conditions of Cells Sources And Clinical Utility In Renal Transplantation
HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA UNIVERSIDAD DE CANTABRIA Intracellular ATP Production By CD4 T Cells Comparison of Different Conditions of Cells Sources And Clinical Utility In Renal Transplantation
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29755 holds various files of this Leiden University dissertation. Author: Moes, Dirk Jan Alie Roelof Title: Optimizing immunosuppression with mtor inhibitors
More informationVictims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham
Victims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham Disclosure Employee: CTI Clinical Trials and Consulting
More informationRon Shapiro, MD, Abdul S. Rao, MD, D. Phil., Paulo Fontes, MD, Adrianna Zeevi, Ph.D., Mark Jordan, MD, Velma P. Scantlebury, MD,
Kidney IBone Marrow Transplantation Ron Shapiro, MD, Abdul S. Rao, MD, D. Phil., Paulo Fontes, MD, Adrianna Zeevi, Ph.D., Mark Jordan, MD, Velma P. Scantlebury, MD, Carlos Vivas, MD, H. Albin Gritsch,
More informationCardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: CICLOSPORIN Protocol number: CV 06
Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: CICLOSPORIN Protocol number: CV 06 Indication: RENAL, PANCREAS OR COMBINED RENAL PANCREAS TRANSPLANTATION IN ADULTS
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationCases: CMV, HCV, BKV and Kidney Transplantation. Simin Goral, MD University of Pennsylvania Medical Center
Cases: CMV, HCV, BKV and Kidney Transplantation Simin Goral, MD University of Pennsylvania Medical Center Disclosures Grant support: Otsuka Pharmaceuticals, Astellas Pharma, Angion, AstraZeneca, and Kadmon
More informationCST/CSN COMMENTARY INTRODUCTION REVIEW AND APPROVAL PROCESS FOR THIS COMMENTARY
CST/CSN COMMENTARY Canadian Society of Transplantation and Canadian Society of Nephrology Commentary on the 2009 KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients Greg A. Knoll,
More informationEvaluation of the QuantiFERON- CMV assay as a monitoring tool in solid organ and allogenic stem cell transplantation
Evaluation of the QuantiFERON- CMV assay as a monitoring tool in solid organ and allogenic stem cell transplantation Dr Grace Thompson A/Prof Mina John CMV in transplantation Major cause of morbidity and
More informationCommon Infections in Kidney Transplant Recipients
In-Depth Review Common Infections in Kidney Transplant Recipients Shamila Karuthu* and Emily A. Blumberg Summary Infections are a major cause of morbidity and mortality in kidney transplant recipients.
More informationMichael Grimley 1, Vinod Prasad 2, Joanne Kurtzberg 2, Roy Chemaly 3, Thomas Brundage 4, Chad Wilson 4, Herve Mommeja-Marin 4
Twice-weekly Brincidofovir (BCV, CMX1) Shows Promising Antiviral Activity in Immunocompromised Transplant Patients with Asymptomatic Adenovirus Viremia Michael Grimley 1, Vinod Prasad, Joanne Kurtzberg,
More informationIntruduction PSI MODE OF ACTION AND PHARMACOKINETICS
Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation Andreas Zuckermann, MD et al. Department of Cardio-Thoracic Surgery, Medical University
More informationLiver Transplant Immunosuppression
Liver Transplant Immunosuppression Michael Daily, MD, MS, FACS Surgical Director, Kidney and Pancreas Transplantation University of Kentucky Medical Center Disclosures No financial disclosures I will be
More informationSteroid Minimization: Great Idea or Silly Move?
Steroid Minimization: Great Idea or Silly Move? Disclosures I have financial relationship(s) within the last 12 months relevant to my presentation with: Astellas Grants ** Bristol Myers Squibb Grants,
More informationNAPRTCS Annual Transplant Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2014 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE II TRANSPLANTATION Section
More informationChapter 6: Transplantation
Chapter 6: Transplantation Introduction During calendar year 2012, 17,305 kidney transplants, including kidney-alone and kidney plus at least one additional organ, were performed in the United States.
More informationNAPRTCS Annual Transplant Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2010 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE I INTRODUCTION 1 II
More informationI hope the shared cared protocol will help with your care of this renal transplant patient. We are happy to discuss any issues with you.
Paediatric Nephrology Phone (64) 9-3078900 Fax (64) 9-3078938 renalnurse@adhb.govt.nz wwong@adhb.govt.nz tonyak@adhb.govt.nz stackm@adhb.govt.nz chanelp@adhb.govt.nz Dear Colleague, Thank you for resuming
More informationTolerance Induction in Transplantation
Tolerance Induction in Transplantation Reza F. Saidi, MD, FACS, FICS Assistant Professor of Surgery Division of Organ Transplantation Department of Surgery University of Massachusetts Medical School Percent
More informationReduced graft function (with or without dialysis) vs immediate graft function a comparison of long-term renal allograft survival
Nephrol Dial Transplant (2006) 21: 2270 2274 doi:10.1093/ndt/gfl103 Advance Access publication 22 May 2006 Original Article Reduced graft function (with or without dialysis) vs immediate graft function
More informationTransplant Hepatology
Transplant Hepatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified
More informationK For patients who have never been tested for HCV, it is. K It is suggested that HCV-infected patients not previously
http://www.kidney-international.org & 2008 DIGO Guideline 4: Management of HCV-infected patients before and after kidney transplantation idney International (2008) 73 (Suppl 109), S53 S68; doi:10.1038/ki.2008.87
More informationCardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: TACROLIMUS Protocol number: CV 43
Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: TACROLIMUS Protocol number: CV 43 Indications: RENAL, PANCREAS OR COMBINED RENAL PANCREAS TRANSPLANTATION IN ADULTS.
More informationclevelandclinic.org/transplant
carolyn spiotta Pancreas/Kidney Transplant Recipient I feel so fortunate and thankful that I have received a second chance at life. Carolyn Spiotta, 44, Pittsburgh. Carolyn needed a new pancreas and kidney
More informationHow do the KDIGO Clinical Practice Guidelines on the Care of Kidney Transplant Recipients apply to the UK?
How do the KDIGO Clinical Practice Guidelines on the Care of Kidney Transplant Recipients apply to the UK? Dr Richard Baker & Professor Alan Jardine, co-authors, forthcoming Renal Association module on
More informationHealth technology Two prophylaxis schemes against organ rejection in renal transplantation were compared in the study:
An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation Polsky D, Weinfurt K P, Kaplan B, Kim J, Fastenau J, Schulman K A Record Status
More informationClinicalValidation Study of Quantitative Real-Time PCR Assay for Detection and Monitoring of BK Virus Nephropathy
Available online at www.annclinlabsci.org ClinicalValidation Study of Quantitative Real-Time PCR Assay for Detection and Monitoring of BK Virus Nephropathy 455 Satoru Kudose 1 and Jianli Dong 2 Departments
More informationPotential Catalysts in Therapeutics
LIVER TRANSPLANTATION 20:S22 S31, 2014 SUPPLEMENT Potential Catalysts in Therapeutics Bruce A. Luxon Division of Gastroenterology-Hepatology, University of Iowa, Iowa City, IA Received July 23, 2014; accepted
More informationSignificance of Basiliximab Induction Therapy in Standard-Risk Renal Transplant in Tacrolimus Era: A Meta-Analysis
Significance of Basiliximab Induction Therapy in Standard-Risk Renal Transplant in Tacrolimus Era: A Meta-Analysis Hatem Ali 1,2, Atif Mohiuddin 2,3, Ajay Sharma 2,3, Mohsen El Kosi 2,4 and Ahmed Halawa
More informationThe privilege of induction avoidance and calcineurin inhibitors withdrawal in 2 haplotype HLA matched white kidney transplantation
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2017 The privilege of induction avoidance and calcineurin inhibitors withdrawal in 2 haplotype HLA matched white
More informationTRANSPLANTATION IN DIABETIC PATIENTS. A.Tarik Kizilisik, MD, MSc, FACS, FICS Director & Primary Transplant Surgeon Lutheran Transplant Center
TRANSPLANTATION IN DIABETIC PATIENTS A.Tarik Kizilisik, MD, MSc, FACS, FICS Director & Primary Transplant Surgeon Lutheran Transplant Center Diabetes is the pandemic of the new millennium 24 million diabetics
More informationProspective, Randomized, Multi-Center Trial of Antibody Induction Therapy in Simultaneous Pancreas-Kidney Transplantation
American Journal of Transplantation 2003; 3: 855 864 Copyright # Blackwell Munksgaard 2003 Blackwell Munksgaard ISSN 1600-6135 Prospective, Randomized, Multi-Center Trial of Antibody Therapy in Simultaneous
More informationDisclosures. CMV and EBV Infection in Pediatric Transplantation. Goals. Common Aspects CMV (Cytomegalovirus) and EBV (Epstein-Barr virus)
Disclosures I have financial relationships with the following companies: CMV and EBV Infection in Pediatric Transplantation Elekta Inc Lucence Diagnostics Spouse employed Spouse employed I will not discuss
More informationPREVENTION AND TREATMENT OF BKV NEPHROPATHY Petra Reinke, Berlin, Germany. Chair: Daniel Abramowicz, Brussels, Belgium Rosanna Coppo, Turin, Italy
PREVENTION AND TREATMENT OF BKV NEPHROPATHY Petra Reinke, Berlin, Germany Chair: Daniel Abramowicz, Brussels, Belgium Rosanna Coppo, Turin, Italy Prof Petra Reinke Department of Nephrology University Hospital
More informationLack of Significant Co-Activation of BKV and CMV in Renal Transplant Patients: An Institutional Experience
Volume 1, Issue 1, pp: 1-6 Research Article Introduction Open Access Lack of Significant Co-Activation of BKV and CMV in Renal Transplant Patients: An Institutional Experience Minh-Thu Nguyen, BS 1, Phylicia
More informationI hope the shared cared protocol will help with your care of this renal transplant patient. We are happy to discuss any issues with you.
Paediatric Nephrology Phone (64) 9-3078900 Fax (64) 9-3078938 renalnurse@adhb.govt.nz wwong@adhb.govt.nz tonyak@adhb.govt.nz stackm@adhb.govt.nz chanelp@adhb.govt.nz Dear Colleague, Thank you for resuming
More informationWhy Do We Need New Immunosuppressive Agents
Why Do We Need New Immunosuppressive Agents 1 Reducing acute rejection rates has not transplanted into better long-term graft survival Incidence of early acute rejection episodes by era Relative risk for
More informationPharmacology notes Interleukin-2 receptor-blocking monoclonal antibodies: evaluation of 2 new agents
BUMC Proceedings 1999;12:110-112 Pharmacology notes Interleukin-2 receptor-blocking monoclonal antibodies: evaluation of 2 new agents CHERYLE GURK-TURNER, RPH Department of Pharmacy Services, BUMC wo mouse/human
More informationDiagnosis and Management of Acute and Chronic Humoral Rejection. Lars Pape
Diagnosis and Management of Acute and Chronic Humoral Rejection Lars Pape Immunosuppression Acute rejection Chronic rejection Side effects Infections Nephrotoxicity Adult population Nearly all late rejection-related
More informationMarta Farrero Torres₁, Marcelo Pando₂, Dolly Tyan₂, Hannah Valantine₃, Spenser Smith₃, Kiran Khush₃
Development of HLA donor specific antibodies after heart transplantation: importance of a new method to detect the first component of the complement cascade Marta Farrero Torres₁, Marcelo Pando₂, Dolly
More information